Vir Biotechnology DEF 14A: Executive Compensation Details

Ticker: VIR · Form: DEF 14A · Filed: 2025-04-17T00:00:00.000Z

Sentiment: neutral

Topics: executive-compensation, proxy-statement, board-of-directors, equity-awards

Related Tickers: VIR

TL;DR

Vir Bio's DEF 14A drops, showing exec pay & equity awards for 2024. Scangos & DeBacker compensation detailed.

AI Summary

Vir Biotechnology, Inc. filed a DEF 14A on April 17, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and board member information, including compensation for Dr. Scangos and Dr. DeBacker for the years 2020 through 2024. It also outlines equity awards granted to both PEO and Non-PEO NEO members.

Why It Matters

This filing provides transparency into how Vir Biotechnology compensates its top executives and board members, which can influence investor perception and company governance.

Risk Assessment

Risk Level: low — This is a routine DEF 14A filing detailing executive compensation and board information, not indicating any immediate operational or financial risks.

Key Numbers

2024 — Fiscal Year End (The period for which compensation and equity awards are detailed.)
2020-2024 — Compensation Reporting Period (The range of years for which executive compensation data is provided.)

Key Players & Entities

Vir Biotechnology, Inc. (company) — Filer of the DEF 14A
Dr. Scangos (person) — Executive/Board Member mentioned in compensation details
Dr. DeBacker (person) — Executive/Board Member mentioned in compensation details
1800 Owens Street, Suite 900, San Francisco, CA 94158 (location) — Company's business and mailing address

FAQ

What is the primary purpose of a DEF 14A filing?

A DEF 14A filing, also known as a Definitive Proxy Statement, is filed by a company to solicit proxies from shareholders for an upcoming annual or special meeting. It provides detailed information about matters to be voted on, including executive compensation, director elections, and other corporate governance issues.

Who are the key individuals whose compensation is detailed in this filing?

The filing details compensation and equity awards for individuals identified as 'Dr. Scangos' and 'Dr. DeBacker', who are associated with equity awards for PEO (Principal Executive Officer) and Non-PEO NEO (Non-Principal Executive Officer Named Executive Officer) roles.

What is the reporting period covered by the compensation information?

The compensation information and equity awards detailed in this filing cover the fiscal years from 2020 through 2024.

What type of equity awards are mentioned in the filing?

The filing mentions 'EqtyAwrdsInSummryCompstnTblForAplblYrMember' (Equity Awards in Summary Compensation Table for Applicable Year Member) and 'YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember' (Year-End Fair Value of Equity Awards Granted in Covered Year Outstanding and Unvested Member), indicating grants of equity awards.

When was this DEF 14A filing submitted to the SEC?

This DEF 14A filing was submitted to the SEC on April 17, 2025.

From the Filing

0001628280-25-018119.txt : 20250417 0001628280-25-018119.hdr.sgml : 20250417 20250417083355 ACCESSION NUMBER: 0001628280-25-018119 CONFORMED SUBMISSION TYPE: DEF 14A PUBLIC DOCUMENT COUNT: 43 CONFORMED PERIOD OF REPORT: 20250529 FILED AS OF DATE: 20250417 DATE AS OF CHANGE: 20250417 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vir Biotechnology, Inc. CENTRAL INDEX KEY: 0001706431 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 812730369 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEF 14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-39083 FILM NUMBER: 25844388 BUSINESS ADDRESS: STREET 1: 1800 OWENS STREET STREET 2: SUITE 900 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-906-4324 MAIL ADDRESS: STREET 1: 1800 OWENS STREET STREET 2: SUITE 900 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 DEF 14A 1 vir-20250417.htm DEF 14A vir-20250417 0001706431 false DEF 14A iso4217:USD 0001706431 2024-01-01 2024-12-31 0001706431 vir:Dr.ScangosMember 2024-01-01 2024-12-31 0001706431 vir:Dr.DeBackerMember 2024-01-01 2024-12-31 0001706431 vir:Dr.ScangosMember 2023-01-01 2023-12-31 0001706431 vir:Dr.DeBackerMember 2023-01-01 2023-12-31 0001706431 2023-01-01 2023-12-31 0001706431 vir:Dr.ScangosMember 2022-01-01 2022-12-31 0001706431 vir:Dr.DeBackerMember 2022-01-01 2022-12-31 0001706431 2022-01-01 2022-12-31 0001706431 vir:Dr.ScangosMember 2021-01-01 2021-12-31 0001706431 vir:Dr.DeBackerMember 2021-01-01 2021-12-31 0001706431 2021-01-01 2021-12-31 0001706431 vir:Dr.ScangosMember 2020-01-01 2020-12-31 0001706431 vir:Dr.DeBackerMember 2020-01-01 2020-12-31 0001706431 2020-01-01 2020-12-31 0001706431 ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember ecd:PeoMember 2024-01-01 2024-12-31 0001706431 ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001706431 ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember ecd:PeoMember 2024-01-01 2024-12-31 0001706431 ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001706431 ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember ecd:PeoMember 2024-01-01 2024-12-31 0001706431 ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001706431 ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember ecd:PeoMember 2024-01-01 2024-12-31 0001706431 ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001706431 ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember ecd:PeoMember 2024-01-01 2024-12-31 0001706431 ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001706431 ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember ecd:PeoMember 2024-01-01 2024-12-31 0001706431 ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001706431 ecd:DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember ecd:PeoMember 2024-01-01 2024-12-31 0001706431 ecd:DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) Filed by the Registrant x Filed by a Party other than the Registrant   o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material Pursuant to §240.14a-12 Vir Biotechnology, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (C